Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: Development of inhibitors with broad spectrum, Gram-negative antibacterial activity

Micheal Trzoss(Arcturus Therapeutics (United States)), Leslie W. Tari(Arcturus Therapeutics (United States)), Junhu Zhang(Jilin University), Vickie Brown‐Driver(Arcturus Therapeutics (United States)), Mark A. Stidham(Arcturus Therapeutics (United States)), Thanh Lam(Arcturus Therapeutics (United States)), Bryan P. Kwan(Arcturus Therapeutics (United States)), Christopher J. Creighton(Arcturus Therapeutics (United States)), Amanda Castellano(Arcturus Therapeutics (United States)), Daniel C. Bensen(State Street (United States)), Karen Joy Shaw(Arcturus Therapeutics (United States)), Zhiyong Chen(China Guangzhou Analysis and Testing Center), Xiaoming Li(Qiqihar Medical University), John Finn(Arcturus Therapeutics (United States)), Toan B. Nguyen(Lawrence Livermore National Laboratory), Mark L. Cunningham(Arcturus Therapeutics (United States)), Felice C. Lightstone, Sergio Wong(Lawrence Livermore National Laboratory), Kirk Nelson(Arcturus Therapeutics (United States))
Bioorganic & Medicinal Chemistry Letters
December 8, 2012
Cited by 81


Related Papers